Naming the first of three business leaders for
its newly created market segments and nominating new Independent
Director to its Board
LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc
(NYSE: CLVT), a global leader in connecting people and
organizations to intelligence they can trust, today announced that
Gordon Samson, currently Chief
Product Officer, has been appointed President of its Intellectual
Property (IP) market segment, effective April 1. The Company also announced that it has
nominated Dr. Saurabh Saha to stand
for election as a director at its 2023 Annual General Meeting of
shareholders on May 4, 2023.
Jonathan Gear, Chief Executive
Officer, Clarivate said: "I'm very pleased to announce the
appointment of Gordon who has been a trusted and valued member of
our Executive Leadership Team since he came to Clarivate from CPA
Global as part of our acquisition in 2020. In this newly created
role, he will be responsible for accelerating the growth of our IP
segment empowering customers to establish, protect and manage their
IP.
Based on my experience working with him over the last eight
months and the work we've done this year to align the organization,
I'm confident that he will be instrumental to how we capitalize on
product and service innovation to deliver organic growth. This is
the first of our presidential appointments and we look forward to
providing updates on further appointments in due course."
Samson joined Clarivate in October
2020 with the acquisition of CPA Global, having joined CPA
Global in 2014 as Chief Operating Officer. During the last three
years with Clarivate, Samson has made significant contributions,
helping transform the Company's APAC region and bringing together
the Company's entire product portfolio to offer customers a full
range of enriched data, insights, analytics and workflow solutions.
He has a long and successful track record of driving organizational
transformation and growth in the IP industry and beyond, having
held senior executive roles with both operating and P&L
accountability for more than 20 years.
Andy Snyder, Chairman of the
Board, Clarivate commented: "We look forward to Dr. Saha joining
our Board. He will bring a great deal of experience in the
pharmaceutical and biotech industries and his guidance will provide
valuable insights and perspective, especially as we continue to
execute on our growth strategy in the Life Sciences &
Healthcare segment."
Dr. Saha is a physician-scientist, pharmaceutical executive, and
biotech entrepreneur dedicated to discovering and developing novel
life-changing medicines. He is notable for leading the development
and demonstrating human effectiveness of two innovative cancer
drugs, an ERK kinase inhibitor (Ulixertinib) and an oncolytic
immunotherapy (C. novyi-NT). He is currently CEO of Centessa
Pharmaceuticals (NASDAQ: CNTA), a global pharma company. Prior to
Centessa, Dr. Saha was a Senior Vice President of R&D and
Global Head of Translational Medicine for all disease areas at
Bristol Myers Squibb. Other past roles include Venture Partner at
Atlas Venture, a VC firm in Cambridge
MA, Chief Executive Officer at Delinia, Chief Medical
Officer of Synlogic, a management consultant at McKinsey &
Company, and head of the New Indications Discovery Unit at
Novartis. He is an associate member and Global Clinical Scholar at
Harvard Medical School, holds an MD and
PhD in medicine and cancer genetics from The Johns Hopkins School of Medicine, an MSc in
biophysics from the University of
Oxford and a BSc in biochemistry from Caltech.
About Clarivate
Clarivate™ is a leading global information services provider. We
connect people and organizations to intelligence they can trust to
transform their perspective, their work and our world. Our
subscription and technology-based solutions are coupled with deep
domain expertise and cover the areas of Academia & Government,
Life Sciences & Healthcare and Intellectual Property. For more
information, please visit clarivate.com.
Investor Relations Contact
Mark Donohue, Head of Investor Relations,
investor.relations@clarivate.com, +1 (215) 243 2202
Media Contact
Amy
Bourke-Waite, Senior Director, Corporate Communications,
newsroom@clarivate.com
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/clarivate-announces-gordon-samson-as-president-intellectual-property-and-nominates-dr-saurabh-saha-as-new-independent-director-301780131.html